Smoking Cessation as a Public Health Measure to Limit the Pandemic of COVID-19
May 06, 2020
Overview:By Maki Komiyama, Koji Hasegawa National Hospital Organization Kyoto Medical Center, Kyoto, Japan Background COVID-19, which is caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2, commonly called the novel coronavirus), to be a public health emergency of international concern.1... more
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease : A Randomized Trial
Jun 17, 2013
Overview:Expert Review: Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease : A Randomized Trial Reviewer: Amelia Carro. Hospital Universitario Vall d’Hebrón. Universidad Autónoma de Barcelona, Barcelona, Spain. Date: June 13th, 2013 Background First-line pharmacological interventions... more
Significance of LOX-1 in cardiovascular function and its application for therapeutic diagnosis
Apr 28, 2017
Overview:Tatsuya Sawamura, MD, PhD Professor, Department of Physiology, Shinshu University LDL is a “bad” cholesterol in the blood that is involved in the progression of arteriosclerosis. Particular focus has been placed on modified LDL, such as LDL that has been... more
FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil
Apr 28, 2017
Overview:By : Dimitrios Tziakas, MD,PhD, Georgios Chalikias, MD,PhD The US Food and Drug Administration (FDA) has recently ( July 2013) issued a safety announcement that the blood pressure drug olmesartan medoxomil can cause intestinal problems known as sprue-like enteropathy... more
FDA approves new safety labeling for statins
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain The US Food and Drug Administration (FDA) approved a new labeling indicating that taking a statin can raise blood sugar and glycosylated hemoglobin HbA1c levels. This new labelling is valid for all statins. The... more
Improving persistence and clinical results of drug therapy: the role of a polypill
Jul 25, 2017
Overview:By Dr José María Castellano In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical... more
Drug Therapy of Hypertension
Jan 25, 2018
Overview:By Wilbert S. Aronow, MD, FACC and Julio A. Panza, MD, FACC* Although lifestyle measures are an essential part of the treatment of hypertension, antihypertensive drugs are required in the vast majority of patients in order to achieve their blood pressure... more
Bleeding Prevention and Treatment
Jul 25, 2017
Overview:By Dr Martínez Selles The assessment of any kind of bleeding event in a NOACs patient is quite different from an AVK (antivitamin-K) dependent patient. There are questions to take into consideration, such as the onset, the severity and the... more
Prior antiplatelet or anticoagulant therapy and mortality in stroke
Jun 18, 2012
Overview:The authors of the present study investigated the influence of previous antiplatelet (AP) or anticoagulant (AC) therapy on subsequent stroke mortality at different time points up to one year post stroke. The authors found that prior antiplatelet or anticoagulant use... more
Expert review: Dual-Antiplatelet Therapy
May 17, 2012
Overview:Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial Background Major advances in the treatment of coronary heart disease, both stable angina and acute coronary syndromes, have involved improvements in percutaneous coronary intervention; and a... more